These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33299899)

  • 1. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
    Dos Anjos F; Simões JLB; Assmann CE; Carvalho FB; Bagatini MD
    J Immunol Res; 2020; 2020():8632048. PubMed ID: 33299899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.
    Korb VG; Schultz IC; Beckenkamp LR; Wink MR
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting adenosinergic pathway and adenosine A
    Abouelkhair MA
    Med Hypotheses; 2020 Nov; 144():110012. PubMed ID: 32590324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of purinergic signaling in COVID-19.
    Franciosi MLM; Lima MDM; Schetinger MRC; Cardoso AM
    Mol Cell Biochem; 2021 Aug; 476(8):2891-2898. PubMed ID: 33740184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
    Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
    Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
    Zarei M; Sahebi Vaighan N; Ziai SA
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
    Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
    J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
    Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
    Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
    Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
    Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonists and Antagonists for Purinergic Receptors.
    Müller CE; Baqi Y; Namasivayam V
    Methods Mol Biol; 2020; 2041():45-64. PubMed ID: 31646479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases.
    Andrejew R; Glaser T; Oliveira-Giacomelli Á; Ribeiro D; Godoy M; Granato A; Ulrich H
    Adv Exp Med Biol; 2019; 1201():275-353. PubMed ID: 31898792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting purinergic receptors to attenuate inflammation of dry eye.
    Wang JN; Fan H; Song JT
    Purinergic Signal; 2023 Mar; 19(1):199-206. PubMed ID: 35218451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purinergic signaling in diabetes and metabolism.
    Jain S; Jacobson KA
    Biochem Pharmacol; 2021 May; 187():114393. PubMed ID: 33359363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2.
    Hernandez CA; Eugenin EA
    Curr Opin Pharmacol; 2023 Dec; 73():102404. PubMed ID: 37734241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
    Nadeali Z; Mohammad-Rezaei F; Aria H; Nikpour P
    Life Sci; 2022 May; 297():120482. PubMed ID: 35288174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
    Yoshida K; Ito M; Matsuoka I
    Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release.
    Varani K; Padovan M; Vincenzi F; Targa M; Trotta F; Govoni M; Borea PA
    Arthritis Res Ther; 2011; 13(6):R197. PubMed ID: 22146575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
    DiNicolantonio JJ; Barroso-Aranda J
    Med Hypotheses; 2020 Oct; 143():110051. PubMed ID: 32650197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic signalling in host innate immune defence against intracellular pathogens.
    Coutinho-Silva R; Savio LEB
    Biochem Pharmacol; 2021 May; 187():114405. PubMed ID: 33406411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium.
    Bergamin LS; Braganhol E; Figueiró F; Casali EA; Zanin RF; Sévigny J; Battastini AM
    J Cell Biochem; 2015 May; 116(5):721-9. PubMed ID: 25546398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.